GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fortrea Holdings Inc (MEX:FTRE1) » Definitions » Inventories, Raw Materials & Components

Fortrea Holdings (MEX:FTRE1) Inventories, Raw Materials & Components : MXN0 Mil (As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Fortrea Holdings Inventories, Raw Materials & Components?

Fortrea Holdings's inventories, raw materials & components for the quarter that ended in Dec. 2024 was MXN0 Mil.


Fortrea Holdings Inventories, Raw Materials & Components Historical Data

The historical data trend for Fortrea Holdings's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fortrea Holdings Inventories, Raw Materials & Components Chart

Fortrea Holdings Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Inventories, Raw Materials & Components
- - - - -

Fortrea Holdings Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Inventories, Raw Materials & Components Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Fortrea Holdings Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.


Fortrea Holdings Business Description

Industry
Traded in Other Exchanges
Address
8 Moore Drive, Durham, NC, USA, 27709
Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.

Fortrea Holdings Headlines

No Headlines